Why the study?
Studies suggest an inverse correlation between AAA and diabetes, particularly with metformin treatment, but this relationship remains unclear.
Does metformin reduce AAA growth rate and AAA-related events in patients with abdominal aortic aneurysm?
Population
11 articles comprising 13 cohorts (32,250 metformin users and 116,339 controls)
Comparison
Metformin vs non-metformin control treatments
Design
Systematic review and random effects meta-analysis
Key result
Metformin use was associated with a slower abdominal aortic aneurysm growth rate (WMD -0.86 mm; 95% CI -1.21 to -0.52; p<0.01) and fewer AAA-related events (OR 0.54; 95% CI 0.34 to 0.86; p=0.01).
Authors
Loading...
May support metformin evaluation in AAA; hypothesis-generating from observational data and requires RCT confirmation.
Meta-Analysis (n=148,589)
Does metformin reduce AAA growth rate and AAA-related events in patients with abdominal aortic aneurysm?
Mean Difference: -0.86 (95% CI -1.21–-0.52)
p-value: p=<0.01
Metformin use is associated with a significantly slower growth rate of abdominal aortic aneurysms and a reduction in AAA-related events.
Dewangga et al. (2024) conducted a meta-analysis in Abdominal aortic aneurysm (n=148,589). Metformin vs. Non-metformin treatments was evaluated on AAA growth rate (WMD -0.86, 95% CI -1.21 to -0.52, p=<0.01). Metformin use was associated with a slower abdominal aortic aneurysm growth rate (WMD -0.86 mm; 95% CI -1.21 to -0.52; p<0.01) and fewer AAA-related events (OR 0.54; 95% CI 0.34 to 0.86; p=0.01).